A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Clinical trial NCT05082610 · COMPLETED
Trial details
- NCT number
- NCT05082610
- Sponsor
- Hummingbird Bioscience
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2024-11-05
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.